Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05973084 · ClinicalTrials.gov registry record
COVID-19 Transmission and Morbidity in Malawi
A clinical trial of SARS CoV 2 Infection and SARS CoV 2 Vaccination, sponsored by Boston University.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 2
- Study locations
NCT05973084 is a study of SARS CoV 2 Infection and SARS CoV 2 Vaccination that is actively recruiting participants, run by Boston University. The registered enrollment target is 1,500 participants, below the 4,912-participant average among 28 other SARS CoV 2 Infection trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05973084, a study of SARS CoV 2 Infection and SARS CoV 2 Vaccination, is actively recruiting participants, sponsored by Boston University.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 2
- Study locations
Study Summary
SARS-CoV-2 transmission was expected to have a devastating impact in sub-Saharan African countries. Instead, morbidity and mortality rates in nearly the whole region are an order of magnitude lower than in Europe and the Americas. To identify what is different requires a better understanding of the underlying immunological substrate of the population, and how these factors affect susceptibility to infection, progression of symptoms, transmission, and responses to SARS-CoV-2 vaccination. Study objectives 1. Determine the risk and predictors of infection and disease among contacts of SARS-CoV-2 infection subjects in Malawi 2. Determine whether innate immune responses lower the risk of SARS-CoV-2 infection and disease, and acquisition and duration of vaccine responses. 3. Assess whether alterations in innate immune responses relevant to SARS-CoV-2 are associated with malaria or intestinal parasite infections. 4. Assess the acquisition and longevity of antibodies (Ab) and cellular adaptive responses elicited by SARS-CoV-2 infection and vaccination. 5. Assess whether malaria and intestinal parasite infections, chronic/mild undernutrition, and anemia mediate alterations in Ab and other adaptive cellular responses to SARS-CoV-2 through innate immune responses or a different unknown mechanism.
Conditions Studied
Study Locations (2)
Massachusetts
- BU School of Public Health, Global Health Department - Boston
Other
- Health center - Blantyre
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2028-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05973084
The ClinicalTrials.gov registry entry for NCT05973084 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,912-participant average among 28 other SARS CoV 2 Infection trials with a reported enrollment target (69% lower). The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with SARS CoV 2 Infection appearing as the primary indexed condition, and to 0 interventions.
NCT05973084 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Other.
Frequently Asked Questions
What is clinical trial NCT05973084 about?
NCT05973084 is a clinical study titled "COVID-19 Transmission and Morbidity in Malawi". SARS-CoV-2 transmission was expected to have a devastating impact in sub-Saharan African countries. Instead, morbidity and mortality rates in nearly the whole region are an order of magnitude lower than in Europe and the Americas. To identify what is different requires a better understanding of the ...
What is the current status of trial NCT05973084?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2023-01-17. Estimated completion is 2028-03.
What conditions does trial NCT05973084 study?
This clinical trial studies the following conditions: SARS CoV 2 Infection, SARS CoV 2 Vaccination.
Who is sponsoring clinical trial NCT05973084?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05973084 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS CoV 2 Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise in Child Health
RECRUITING · NA
-
NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
RECRUITING
-
Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome
RECRUITING · NA
-
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
RECRUITING · Phase 2
-
CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2
RECRUITING
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.